U.K., Denmark, Iceland all go for Boehringer Ingelheim COPD drug Striverdi Respimat

Boehringer Ingelheim has gotten approval in the U.K., Denmark and Iceland for Striverdi Respimat. The new COPD therapy is a successor to its $4.7 billion-a-year Spiriva franchise. The drug has not yet been approved in the U.S; an FDA panel recommended it but said Striverdi has little to set it apart from COPD treatments already on the market. The FDA is expected to approve it, but some analysts wonder how it will fare if a generic of GlaxoSmithKline's ($GSK) Advair makes it to the market. Story | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.